- Home
- PBPB vs ESPR Comparison
PBPB vs ESPR Comparison
Compare PBPB & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- ESPR
- Stock Information
- Founded
- PBPB 1977
- ESPR 2008
- Country
- PBPB United States
- ESPR United States
- Employees
- PBPB 5000
- ESPR N/A
- Industry
- PBPB Restaurants
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- ESPR Health Care
- Exchange
- PBPB Nasdaq
- ESPR Nasdaq
- Market Cap
- PBPB 278.1M
- ESPR 305.0M
- IPO Year
- PBPB 2013
- ESPR 2013
- Fundamental
- Price
- PBPB $9.32
- ESPR $1.69
- Analyst Decision
- PBPB Strong Buy
- ESPR Buy
- Analyst Count
- PBPB 3
- ESPR 7
- Target Price
- PBPB $15.33
- ESPR $6.36
- AVG Volume (30 Days)
- PBPB 345.9K
- ESPR 4.2M
- Earning Date
- PBPB 03-06-2025
- ESPR 03-04-2025
- Dividend Yield
- PBPB N/A
- ESPR N/A
- EPS Growth
- PBPB 670.59
- ESPR N/A
- EPS
- PBPB 1.31
- ESPR N/A
- Revenue
- PBPB $462,598,000.00
- ESPR $332,314,000.00
- Revenue This Year
- PBPB $5.67
- ESPR $5.51
- Revenue Next Year
- PBPB $3.78
- ESPR $1.42
- P/E Ratio
- PBPB $7.11
- ESPR N/A
- Revenue Growth
- PBPB N/A
- ESPR 185.66
- 52 Week Low
- PBPB $6.28
- ESPR $1.47
- 52 Week High
- PBPB $13.48
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- PBPB 34.02
- ESPR 49.78
- Support Level
- PBPB $8.96
- ESPR $1.47
- Resistance Level
- PBPB $9.64
- ESPR $1.61
- Average True Range (ATR)
- PBPB 0.53
- ESPR 0.12
- MACD
- PBPB -0.14
- ESPR 0.02
- Stochastic Oscillator
- PBPB 13.61
- ESPR 56.41
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.